Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of the company’s common stock by affiliated investment funds. Over May 5–7, 2026, entities including MPM Asset Management LLC and MPM BioVentures 2014, L.P. sold a total of 100,581 shares at weighted average prices around $0.63–$0.69 per share under a pre‑established Rule 10b5-1 plan dated March 26, 2026. After these transactions, the affiliated entities collectively hold 1,578,749 shares of Werewolf Therapeutics common stock, reported as indirect holdings. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Werewolf Therapeutics reported a Q1 2026 net loss of $13.5 million, or $0.28 per share. Operating expenses fell to $13.3 million from $18.0 million a year earlier, driven mainly by lower R&D spending. Cash and cash equivalents were $46.5 million as of March 31, 2026, with $10.6 million used in operating activities during the quarter.
The company adopted a 2026 restructuring plan, cutting 64% of its workforce and recording $4.3 million of related charges. Management discloses substantial doubt about its ability to continue as a going concern without additional financing or strategic transactions.
After quarter-end, Werewolf sold its JZP898 program to Jazz Pharmaceuticals for $21.0 million upfront plus a potential $2.0 million, repaid approximately $31.4 million outstanding under its K2 HealthVentures term loan, and agreed to terminate its headquarters lease early for a $2.7 million fee.
Werewolf Therapeutics reported first quarter 2026 results and outlined major corporate moves alongside an ongoing strategic review led by Piper Sandler. The company entered an asset purchase agreement giving Jazz Pharmaceuticals exclusive global rights to JZP898 and repaid all amounts owed under its loan with K2 HealthVentures.
Cash and cash equivalents were $46.5 million as of March 31, 2026, down from $57.1 million at year-end 2025. First quarter research and development expenses fell to $8.2 million from $13.1 million a year earlier, while general and administrative expenses were $5.1 million, slightly above $4.9 million in 2025. Net loss narrowed to $13.5 million from $18.1 million, or $0.28 per basic and diluted share versus $0.40.
Working capital declined to $10.2 million and stockholders’ equity to $12.2 million as of March 31, 2026, reflecting continued operating losses and leverage, including $28.8 million of notes payable before the subsequent loan repayment.
MPM-affiliated funds and managers filed Amendment No. 6 to Schedule 13D reporting their ownership of Werewolf Therapeutics, Inc. common stock. Dr. Ansbert Gadicke is reported as beneficially owning 2,608,501 shares, representing 5.4% of the outstanding common stock. The filing cites 48,596,817 shares outstanding as of March 20, 2026.
The group details holdings across multiple entities, including MPM BioVentures 2014, UBS Oncology Impact Fund and related vehicles, with individual funds generally holding between 0.1% and 2.6% of the class. The filing also lists recent open-market sales between April 27 and May 5, 2026 at average prices around $0.69–$0.85 per share by several of these entities.